Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00941538
Other study ID # CRCSTNPC
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 2008
Est. completion date December 2023

Study information

Verified date February 2023
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is aimed to estimate the effectiveness of an Epstein-Barr virus (EBV) serology-based screening program to reduce nasopharyngeal carcinoma (NPC) mortality in a cluster randomized controlled trial in an NPC high-risk population. Sixteen towns in Sihui and Zhongshan Cities, China will be selected, with eight allocated to the screening group and eight to the control group. Cantonese residents aged 30-69 years with no history of NPC will be included. Residents in the screening towns will be invited to undergo serum EBV VCA/EBNA1 IgA antibody tests.


Description:

Nasopharyngeal carcinoma (NPC) has a high prevalence in southern China. Sihui and Zhongshan cities are located along the Pearl River in Guangdong Province, China, and are well known for a high incidence of NPC worldwide. During the last 20 years, Screening for NPC has been demonstrated to increase the early detection rate of NPC in endemic regions. It is well shown that the effect of Epstein-Barr virus (EBV) serological antibodies is elevated several years before NPC diagnosis; therefore, EBV antibodies have been considered screening markers for NPC. However, none of the studies have reported the impact of screening on NPC-specific mortality. This study aims to launch a cluster-randomized screening trial with combined VCA/IgA and EBNA1/IgA measurement by ELISA as the primary screening method in these 2 cities to examine the impact of EBV serological screening on NPC-specific mortality. Residents aged 30-69 years in eight screening towns in the intervention group will be invited to EBV antibody tests-IgA antibodies to EBV VCA/IgA and EBV nuclear antigen-1 (EBNA1/IgA) by ELISA. The primary objective of this trial is to assess an estimate of the EBV serological antibody-based screening for NPC on NPC-specific in the populations with a high incidence of NPC


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 87600
Est. completion date December 2023
Est. primary completion date December 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 69 Years
Eligibility Clusters 1. Inclusion criteria 1) the town located in Sihui or Zhongshan city; 2) the town established a tertiary cancer prevention network; 3) the medical staff in the town hospitals agreed to take part in. 2. Exclusion criteria 1) having conducted NPC screening program. Individuals 1. Inclusion criteria 1) being aged 30-69 years; 2) being Cantonese; 3) having signed the informed consent; 4) having an Eastern Cooperative Oncology Group score of 0-2; and 5) having a good physical or psychological condition and consciousness. 2. Exclusion criteria 1) having prevalent NPC.

Study Design


Intervention

Diagnostic Test:
Experimental: Screening with EBV VCA/EBNA1-IgA testing
Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.

Locations

Country Name City State
China Sihui Cancer Institute Sihui Guangdong
China Cancer Research Institute of Zhongshan City Zhongshan Guangdong

Sponsors (3)

Lead Sponsor Collaborator
Sun Yat-sen University Cancer Research Institute of Zhongshan City, Sihui Cancer Institute

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality rate of NPC at 12 years by intervention group NPC mortality rate will be compared between screening group and control group at 12-year follow-up. December, 2019
Secondary All-cause mortality at 12 years by intervention group All-cause mortality rate will be compared between screening group and control group at 12-year follow-up. December, 2019
Secondary NPC incidence at 12 years by intervention group NPC incidence rate will be compared between screening group and control group at 12-year follow-up. December, 2019
Secondary Stage distribution at diagnosis for NPC patients by intervention group Stage distribution will be compared between screening group and control group at 12-year follow-up. December, 2019
Secondary NPC overall survival by cases from the two intervention groups Survival rate will be compared between screening group and control group at 12-year follow-up. December, 2019
Secondary Cost-effectiveness Cost-effectiveness of this screening program will be calculated at 12-year follow-up. December, 2019
See also
  Status Clinical Trial Phase
Completed NCT03079726 - Use of Device Data to Predict Frailty in Individuals
Not yet recruiting NCT05447611 - Role of Empathy in Curative Treatment Outcomes of Non-metastatic Colorectal Cancer.
Completed NCT05268419 - Efficacy and Safety of Ethanol Inhalation on COVID-19 Treatment (a Clinical Trial Study) Phase 3
Completed NCT05042804 - Perioperative Outcome Risk Assessment With Computer Learning Enhancement N/A
Recruiting NCT03628313 - Valvular Aortic Stenosis Prognosis Study
Completed NCT05527678 - 5 Years Quality of Life and Early Mobilization in ICU
Recruiting NCT05088109 - Shock Indices Use for Early Mortality From Septic Shock
Recruiting NCT05073991 - Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR.
Completed NCT05844410 - Evaluation of Corticosteroids Use and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Study
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Recruiting NCT03834246 - Smoke Inhalation Injury in Patients Admitted to Intensive Care
Completed NCT03919032 - Bacterial Infections in Patients With Cirrhosis in Argentina: Clinical and Microbiological Characteristics
Completed NCT05116670 - Comparison of Care Practices, Mortality and Morbidity of Very Preterm Infants Between Two Tertiary Centers in Northwest and South of China
Withdrawn NCT04531839 - Improving Outcome of Very Preterm Infants Using Collaborative Quality Improvement N/A
Recruiting NCT04685278 - Anticardiolipin Autoantibodies and Mortality in Septic Patients
Not yet recruiting NCT03665987 - The Effect of Preoperative Assessment Clinic on Prognosis and Economic Results of Patients With Coexisting Disease.
Completed NCT04049565 - CRP Versus PCT as Bio-markers for Sepsis and in Guiding Antibiotics in Critically Ill Patients
Completed NCT04971278 - Evaluating the Impact of a Supportive Care Program
Recruiting NCT06087315 - Evaluation of a Multi-country Medical Oxygen Program
Completed NCT03344627 - Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients N/A